Maria Rivera-Ch

Maria Rivera-Ch

Auto-generated profile, based on publicly available information

Maria Rivera-Ch

Universidad Peruana Cayetano Heredia

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2007 in Clinical Autonomic Research
Verified
Journal Article
Open access
PDF file
RHRoger Hainsworth
Roger Hainsworth
MDMark J. Drinkhill
Mark J. Drinkhill
MRMaria Rivera-Chira
Maria Rivera-Chira
The effects of hypobaric hypoxia in visitors depend not only on the actual elevation but also on the rate of ascent. Sympathetic activity increases and there are increases in blood pressure and heart rate. Pulmonary vasoconstriction leads to pulmonary hypertension, particularly during exercise. The sympathetic excitation results from hypoxia, partly through chemoreceptor reflexes and partly through altered baroreceptor function. High pulmonary arterial pressures may also cause reflex systemic vasoconstriction. Most permanent high altitude dwellers show excellent adaptation although there are differences between populations in the extent of the ventilatory drive and the erythropoiesis. Some altitude dwellers, particularly Andeans, may develop chronic mountain sickness, the most prominent characteristic of which being excessive polycythaemia. Excessive hypoxia due to peripheral chemoreceptor dysfunction has been suggested as a cause. The hyperviscous blood leads to pulmonary hypertension, symptoms of cerebral hypoperfusion, and eventually right heart failure and death.

7 October 2009 in JAMA
Verified
Journal Article
Closed access
PDF file
TSThomas G. Smith
Thomas G. Smith
NTNick P. Talbot
Nick P. Talbot
CPCatherine Privat
Catherine Privat
MRMaria Rivera-Ch
Maria Rivera-Ch
ANAnnabel H. Nickol
Annabel H. Nickol
PRPeter A. Robbins
Peter A. Robbins
Research from JAMA — Effects of Iron Supplementation and Depletion on Hypoxic Pulmonary Hypertension — Two Randomized Controlled Trials

24 January 2013 in American Journal of Human Biology
Verified
Journal Article
Open access
PDF file
ABAbigail W. Bigham
Abigail W. Bigham
MWMegan J. Wilson
Megan J. Wilson
CJColleen G. Julian
Colleen G. Julian
MKMelisa Kiyamu
Melisa Kiyamu
EVEnrique Vargas
Enrique Vargas
MSMark D. Shriver
Mark D. Shriver
Objectives: High‐altitude hypoxia, or decreased oxygen levels caused by low barometric pressure, challenges the ability of humans to live and reproduce. Despite these challenges, human populations have lived on the Andean Altiplano and the Tibetan Plateau for millennia and exhibit unique circulatory, respiratory, and hematological adaptations to life at high altitude. We and others have identified natural selection candidate genes and gene regions for these adaptations using dense genome scan data. One gene previously known to be important in cellular oxygen sensing, egl nine homolog 1 (EGLN1), shows evidence of positive selection in both Tibetans and Andeans. Interestingly, the pattern of variation for this gene differs between the two populations. Continued research among Tibetan populations has identified statistical associations between hemoglobin concentration and single nucleotide polymorphism (SNP) genotype at EGLN1 and a second gene, endothelial PAS domain protein 1 (EPAS1).Methods: To measure for the effects of EGLN1 and EPAS1 altitude genotypes on hemoglobin concentration among Andean highlanders, we performed a multiple linear regression analysis of 10 candidate SNPs in or near these two genes.Results: Our analysis did not identify significant associations between EPAS1 or EGLN1 SNP genotypes and hemoglobin concentration in Andeans.Conclusions: These results contribute to our understanding of the unique set of adaptations developed in different highland groups to the hypoxia of high altitude. Overall, the results provide key insights into the patterns of geneticadaptation to high altitude in Andean and Tibetan populations. Am. J. Hum. Biol. 25:190–197, 2013.

1 June 2000 in High Altitude Medicine & Biology
Verified
Journal Article
Closed access
Fabiola León-VelardeFabiola León-Velarde
Fabiola León-Velarde
AGAlfredo Gamboa
Alfredo Gamboa
JCJenny A. Chuquiza
Jenny A. Chuquiza
WEWilliams A. Esteba
Williams A. Esteba
MRMaria Rivera-Chira
Maria Rivera-Chira
CCCarlos Monge C.
Carlos Monge C.
There have been a number of reports describing the hematological indicators of Andean residents living at altitudes above 4000 m, but several confounding factors have made the published results difficult to interpret. To clear up the effect of hypoxia on hemoglobin concentration (Hb, g/dL), hematocrit (Hct, %) and red blood cell concentration (RBC, cells/μL), this publication describes and analyzes these variables in children, men, and women from three large and homogeneous populations living at 4355 m (n = 151), 4660 m (n = 400), and 5500 m (n = 273) in the Southern Peruvian Andes. Hb, Hct, and RBC increase with age in men (p < 0.001), as well as in women (p < 0.001) at the three altitudes of the study. In children (boys and girls) living at 5500, Hb increases 11% when compared with children living at 4355 m, and in adults, Hb increases 9.6% when comparing the same altitudes. The maximum percentage increase in Hb with age was 5.6% at 5500 m, in men and 3.2% at 4355 m, in women. The average percentage of difference for the Hb concentration between adult men and women is 6.6% at 4355 m, 9.8% at 4660 m, and 11.6% at 5500 m. The differences in Hb concentration between men and women can only be seen after puberty. Finally, Hb is higher in older than younger women, which confirms the role of menopause in the development of erythremia. The result of this analysis reinforces the notion that Hb and Hct seem to be stable and useful parameters for acclimatization only at moderate altitudes; with aging or with increasing altitude, they may become excessive and lose their efficiency to protect the venous oxygen pressure.

19 January 2012 in Blood
Verified
Journal Article
Closed access
PDF file
NTNick P. Talbot
Nick P. Talbot
SLSamira Lakhal
Samira Lakhal
TSThomas G. Smith
Thomas G. Smith
CPCatherine Privat
Catherine Privat
ANAnnabel H. Nickol
Annabel H. Nickol
PRPeter A. Robbins
Peter A. Robbins
Enhanced erythropoietic drive and iron deficiency both influence iron homeostasis through the suppression of the iron regulatory hormone hepcidin. Hypoxia also suppresses hepcidin through a mechanism that is unknown. We measured iron indices and plasma hepcidin levels in healthy volunteers during a 7-day sojourn to high altitude (4340 m above sea level), with and without prior intravenous iron loading. Without prior iron loading, a rapid reduction in plasma hepcidin was observed that was almost complete by the second day at altitude. This occurred before any index of iron availability had changed. Prior iron loading delayed the decrease in hepcidin until after the transferrin saturation, but not the ferritin concentration, had normalized. We conclude that hepcidin suppression by the hypoxia of high altitude is not driven by a reduction in iron stores.

15 June 2008 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JRJean-Paul Richalet
Jean-Paul Richalet
MRMaria Rivera-Ch
Maria Rivera-Ch
MMMaxime Maignan
Maxime Maignan
CPCatherine Privat
Catherine Privat
IPIsabelle Pham
Isabelle Pham
Fabiola León-VelardeFabiola León-Velarde
Fabiola León-Velarde
Rationale: Monge's disease is characterized by an excessive erythrocytosis, frequently associated with pulmonary hypertension, in high-altitude dwellers. It has a considerable impact on public health in high-altitude regions. A preliminary study demonstrated the efficiency of acetazolamide (Acz) (250 mg/d for 3 wk) in reducing serum erythropoietin and hematocrit. Objectives: Evaluate the efficacy and tolerance of a 6-month treatment with 250 mg Acz that could be chronically implemented and its effects on pulmonary artery pressure and cardiac function. Methods: A two-phase study was performed in patients (hematocrit ⩾ 63%) from Cerro de Pasco, Peru (4,300 m). First phase: a double-blind, placebo-controlled study in 55 patients who received a single dose of either 250 mg Acz (n = 40) or placebo (n = 15) by daily oral administration for 12 weeks. Second phase (open label): after a 4-week washout period, all patients received 250 mg Acz for 12 weeks. Hematocrit, blood gases, clinical outcome, and pulmonary artery circulation were evaluated. Measurements and Main Results: First phase: Acz decreased by 44% the number of polycythemic subjects (P = 0.02), decreased hematocrit from 69 to 64% (P < 0.001), and increased arterial O2 pressure from 42 to 45 mm Hg (P < 0.001). No severe adverse effect or hypokalemia was recorded. The second phase reproduced the effects observed during the first phase, without cumulative effects on hematocrit. A 4-week washout restored basal hematocrit. Only patients who received Acz for 6 months showed a clear reduction in pulmonary vascular resistance. Conclusions: Acz reduces erythrocytosis and improves pulmonary circulation in Monge's disease without adverse effects. Its implementation as a chronic treatment for this disease appears efficient and safe. Clinical trial registered with www.clinicaltrials.gov (NCT00424970).